Last Updated: 24 January 2025
Springbok Analytics, a leader in AI-driven muscle health analysis, has closed a $5 million Series A funding round, which was oversubscribed. This funding will support the company’s growth and enhance its cutting-edge platform for analyzing muscle health.
The round was led by Transition Equity Partners, LLC (TEP) and included participation from prominent investors such as the National Basketball Association, Cartan Capital, and Boston Global (AUS). The valuation following this funding round was not disclosed.
Springbok Analytics is transforming how muscle health is assessed, combining AI technology with rapid MRI scans to deliver detailed and actionable data. Their solutions address key needs in healthcare, elite sports, and longevity, enabling better decision-making for professionals in these fields.
"This investment will enable us to advance our mission to improve muscle health analysis and expand our impact across clinical care, research, and health. We are excited for this next chapter and remain committed to delivering innovative solutions that empower patients, providers, and researchers in the attainment of precision medicine."
Scott Magargee, CEO and Co-Founder of Springbok Analytics
The company plans to use the funds to enhance its AI platform, improving the speed and accuracy of its muscle health assessments. This includes developing new features, expanding the scope of their analyses, and refining the user experience for medical professionals and researchers.
Additionally, Springbok will allocate resources toward expanding its team and building partnerships with healthcare providers and researchers. These efforts aim to increase the availability and impact of their technology across multiple industries, including clinical care and sports performance.
Springbok Analytics was founded by Scott Magargee and Silvia Blemker and is built on over 15 years of scientific research. The company specializes in AI-powered muscle health analytics, offering FDA-cleared technology that transforms MRI scans into 3D visualizations and actionable insights.
Their platform delivers comprehensive data on muscle volume, composition, fat infiltration, and more, addressing the needs of healthcare professionals, researchers, and athletes.
What sets Springbok apart is its ability to provide accurate, scalable solutions that improve decision-making and outcomes in health and performance.
The Series A funding was led by Transition Equity Partners, LLC (TEP), a key backer of Springbok since its early stages. Other notable participants include the National Basketball Association, Cartan Capital, TitletownTech, and Anthropy Partners.
Springbok’s investors bring a diverse range of expertise from healthcare, sports, and technology, positioning the company for further growth. Earlier funding rounds helped the company develop its FDA-cleared technology, laying the groundwork for broader adoption.
